Efforts will focus on the development of FoundationOne ® CDx as a companion diagnostic for Day One’s tovorafenib, which is in late-stage clinical development for pediatric low-grade glioma CAMBRIDGE, ...
Foundation Medicine, Inc., a global, patient-focused precision medicine company , today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne ® CDx ...
FoundationOne Liquid CDx can be used to identify niraparib and abiraterone acetate eligibility in patients with metastatic castration-resistant prostate cancer (mCRPC). According to the American ...
--Landmark approval advances personalized cancer care as an estimated 1 in 3 patients across five common advanced cancers are expected to match with an FDA-approved therapy-- CAMBRIDGE, ...
LYNPARZA was approved based on positive results from the PROfound study for which Foundation Medicine served as the Next-Generation Sequencing (NGS) partner Prostate cancer is the second most common ...
Chugai obtains MHLW approval for FoundationOne CDx Cancer Genomic Profile as companion diagnostic of Alecensa for ALK fusion gene-positive solid tumours: Tokyo Tuesday, May 19, 20 ...
The FDA companion diagnostic designation for FoundationOne CDx may improve access to niraparib/abiraterone acetate for eligible patients with metastatic castration-resistant prostate cancer (mCRPC) ...
FoundationOne CDx can now be used to identify patients with ROS1 fusion-positive non-small cell lung cancer or patients with NTRK fusion-positive solid tumours for whom treatment with Rozlytrek may be ...
Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced plans to launch FoundationOne ® PGx, a pharmacogenetic (PGx) offering to identify genetic differences ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved FoundationOne CDx as a companion diagnostic to identify patients with microsatellite ...
CAMBRIDGE, Mass. & AUSTIN, Texas--(BUSINESS WIRE)-- Foundation Medicine, Inc. and Natera, Inc. (NASDAQ: NTRA), today announced the launch of the research use version of FoundationOne®Tracker, ...
Pillar Biosciences LLC hopes to build a stronger foundation for its multi-cancer in vitro diagnostic, Oncoreveal Dx. The company filed a supplemental application for U.S. FDA premarket approval of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results